Cancer MoonShot 2020 Milestone: Announcing Launch of the Nation’s Largest Pediatric Brain Tumor Atlas
The first major project of the Pediatric Cancer MoonShot 2020
Consortium with a $20MM Award from the Chan Soon-Shiong Institute of
Molecular Medicine to enable the most comprehensive molecular analysis
of brain tumors of all types in children
Goal is to release genomic, transcriptomic and proteomic data from
1,600 patients in next six months, representing the nation’s largest
brain tumor atlas to date
BOSTON–(BUSINESS WIRE)–NantHealth,
Inc.(Nasdaq: NH), a leading next-generation, evidence-based,
personalized healthcare company, the Chan
Soon-Shiong Institute of Molecular Medicine and the collaborators of
the Pediatric
Cancer MoonShot 2020 today announced that they are embarking on one
of the world’s most ambitious pediatric sequencing discovery projects to
date. This initiative will focus on the largest killer of pediatric
cancer patients today: childhood brain tumors.
The Pediatric Brain Tumor Atlas Project, the first project of Pediatric
Cancer MoonShot 2020, brings together the Childhood
Brain Tumor Tissue Consortium (CBTTC), Children’s
Hospital of Philadelphia (CHOP) and the Hyundai
Cancer Genomic Program at CHOC Children’s Hospital to perform
approximately 4,800 whole genome tumor normal RNA analyses for 1,600
children diagnosed with brain tumors. The project is expected to take
just six months to complete. This large library and enormous fount of
information will be made publicly available to all researchers,
nationally and internationally, so they can benefit from this data
trove. The ultimate goal of the project is to discover insights that
lead to improved treatments and ultimately improved outcomes and quality
of life for pediatric brain tumor patients.
“There are 28,000 children age 0-18 with brain tumors in the United
States. Over 4,600 children are newly diagnosed each year,” stated Dr.
Patrick Soon-Shiong, Chairman and CEO of NantWorks
and leader of Cancer MoonShot 2020. “It’s the leading cause of cancer
related to death in children, even surpassing Leukemia. It is not only
our privilege, but it’s our moral imperative to act rapidly and to share
the analysis of this large tumor atlas with the scientists who can use
it in the war against this deadly disease.”
According to BrainTumor.org,
there have only been four FDA approved drugs to treat pediatric brain
tumors in the past 30 years. Between 1998 and 2014, there were 78
investigational brain tumor drugs that entered the clinical trial
evaluation process. Of those, 75 failed. That is a 25:1 failure ratio in
developing new brain tumor treatments over the past two decades.
Dr. Lennie Sender, Executive Director of the Cancer MoonShot 2020
Pediatric, Adolescent and Young Adult Cancer added, “There is tremendous
lack of progress in the treatment of brain tumors in children, which
makes this such an important project. It is the first major initiative
of the pediatric consortium since its launch in Phoenix on February 18,
2015.”
“Over the last three months at CHOP, we evaluated the GPS
Cancer™ test in six patients with brain tumors and compared them to
findings on standard gene panels. Our conclusions were that this was the
most comprehensive proteomic genomic analysis we have seen and provided
significantly more information than current tests available. The
possibility now to establish an Atlas with genomics and proteomics
information will be a major advance in our fight against cancer,” said
Adam C. Resnick, PhD, Director of the Center for Data Driven Discovery
in Biomedicine (D3b) at the Children’s Hospital of Philadelphia. “A new
treatment is not out of reach. This is exciting because the CBTTC
(Childhood Brain Tumor Tissue Consortium) has been bio-banking tissue
for years, but has lacked the necessary funding for research. “We are
grateful that Dr. Soon-Shiong has made this $20 million award to bring
together these important visions. I believe this is a perfect synergy of
efforts to lead to discovery.”
The Chan Soon-Shiong Institute of Molecular Medicine (CSSIOMM) will fund
the project that is expected to cost $20 million.
About NantWorks
NantWorks, LLC, founded by renowned
physician scientist and inventor of the first human nanoparticle
chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the
umbrella organization for the following entities: NantHealth, NantOmics,
NantBio, NantCell, NantPharma, NantVentures and NantCloud. Fact-based
and solution-driven, each of NantWorks’ division entities operates at
the nexus of innovation and infrastructure. The core mission of
NantWorks is convergence and a systems approach to human biology: to
develop and deliver a diverse range of technologies that accelerates
innovation, broaden the scope of scientific discovery, enhance
ground-breaking research, and improve healthcare treatment for those in
need. NantWorks is building an integrated fact-based, genomically and
proteomically-informed, personalized approach to the delivery of care
and the development of next generation diagnostics and therapeutics for
life threatening diseases such as Cancer, Infectious Diseases and
Alzheimer’s. For more information please visit www.nantworks.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About Cancer MoonShot 2020
The Cancer MoonShot 2020 program
is one of the most comprehensive cancer collaborative initiative
launched to date, seeking to accelerate the potential of combination
immunotherapy as the next generation standard of care in cancer
patients. This initiative aims to explore a new paradigm in cancer care
by initiating randomized Phase II trials in patients at all stages of
disease in 20 tumor types in 20,000 patients within the next 36 months.
These findings will inform Phase III trials and the aspirational
moonshot to develop an effective vaccine-based immunotherapy to combat
cancer by 2020. For more information, please visit www.cancermoonshot2020.org and
follow @MoonShot2020 on Twitter.
About GPS Cancer™
GPS Cancer™ is a unique, molecular profile
analysis available through NantHealth. GPS Cancer integrates whole
genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and
quantitative proteomics through mass spectrometry, providing oncologists
with a comprehensive molecular profile of a patient’s cancer and an
assessment of protein pathway function to inform personalized treatment
strategies. GPS Cancer scanning is conducted in CLIA-certified and
CAP-accredited laboratories, and is a key enabler for Cancer MoonShot
2020, the world’s most comprehensive cancer collaborative initiative
seeking to accelerate the potential of combination immunotherapy as the
next generation standard of care in cancer patients. For more
information, visit www.gpscancer.com and
www.cancermoonshot2020.org.
Contacts
NantWorks
Jen Hodson, 562-397-3639
jhodson@nantworks.com
